Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma
Open accessAbstract
Background: The Wnt/β-catenin pathway is closely associated with osteosarcoma (OS) development and metastatic progression. We investigated the antitumor activity of Tegavivint, a novel β-catenin/transducin β-like protein 1 (TBL1) inhibitor, against OS employing in vitro, ex vivo, and in vivo cell line and patient-derived xenograft (PDX) models that recapitulate high risk disease. Methods: The antitumor efficacy of Tegavivint was evaluated in vitro using established OS and PDX-derived cell lines. Use of an ex vivo three-dimensional pulmonary metastasis assay assessed targeting of β-catenin activity during micro- and macrometastatic development. The in vivo activity of Tegavivint was evaluated using chemoresistant and metastatic OS PDX models. Gene and protein expression were quantified by quantitative Reverse transcription polymerase chain reaction or immunoblot analysis. Bone integrity was determined via microCT. All statistical tests were two-sided. Results: Tegavivint exhibited antiproliferative activity against OS cells in vitro and actively reduced micro- and macrometastatic development ex vivo. Multiple OS PDX tumors (n = 3), including paired patient primary and lung metastatic tumors with inherent chemoresistance, were suppressed by Tegavivint in vivo. We identified that metastatic lung OS cell lines (n = 2) exhibited increased stem cell signatures, including enhanced concomitant aldehyde dehydrogenase (ALDH1) and β-catenin expression and downstream activity, which were suppressed by Tegavivint (ALDH1: control group, mean relative mRNA expression = 1.00, 95% confidence interval [CI] = 0.68 to 1.22 vs Tegavivint group, mean = 0.011, 95% CI = 0.0012 to 0.056, P < .001; β-catenin: control group, mean relative mRNA expression = 1.00, 95% CI = 0.71 to 1.36 vs Tegavivint group, mean = 0.45, 95% CI = 0.36 to 0.52, P < .001). ALDH1high PDX-derived lung OS cells, which demonstrated enhanced metastatic potential compared with ALDHlow cells in vivo, were sensitive to Tegavivint. Toxicity studies revealed decreased bone density in male Tegavivint-treated mice (n = 4 mice per group). Conclusions: Tegavivint is a promising therapeutic agent for advanced stages of OS via its targeting of the β-catenin/ALDH1 axis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several cytokines that mediate metastasis may constitute therapeutic targets in osteosarcoma, including IL-6, CXCL8, CCL2 and β-catenin.
“Several of the cytokines that mediate metastasis may also constitute therapeutic targets, including IL-6, CXCL8 (ref.62 ), CCL2 (ref.99 ) and β-catenin 100 .”
From Osteosarcoma (2022) · cites this paper as [100]
Mouse-derived cultures, from spontaneous tumours or engineered models, allow researchers to examine disease biology or test treatments in mice that have a functioning immune system.
“Cultures derived from mice with spontaneous osteosarcoma 210 or from genetically engineered mouse models 100,213 are available to study disease biology or therapeutics in mice with intact immune systems.”
From Osteosarcoma (2022) · cites this paper as [100]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Wang, S., Zhang, D., Han, S., Gao, P., Liu, C., Li, J., & Pan, X. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-06353-2 · Cited by 40 · see citing works
RetractedWnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554 · see citing works
Identification of c- <i>MYC</i> as a Target of the APC Pathway
He, T.-C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · Science · doi:10.1126/science.281.5382.1509 · Cited by 4,566 · see citing works
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Isakoff, M. S., Bielack, S., Meltzer, P. S., & Gorlick, R. G. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4895 · Cited by 1,578 · see citing works
Stem Cells and Cancer: Two Faces of Eve
Clarke, M. F., & Fuller, M. T. (2006) · Cell · doi:10.1016/j.cell.2006.03.011 · Cited by 899 · see citing works
Essential role of β-catenin in postnatal bone acquisition.
Holmen, S. L., Zylstra, C. R., Mukherjee, A., Sigler, R. E., Faugere, M.-C., Bouxsein, M. L., Deng, L., Clemens, T. L., & Williams, B. O. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501900200 · Cited by 584 · see citing works
Expression of CD44 in Apc and TcfMutant Mice Implies Regulation by the WNT Pathway
Wielenga, V. T., Smits, R., Kořínek, V., Smit, L., Kielman, M. F., Fodde, R., Clevers, H. C., & Pals, S. T. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65297-2 · Cited by 512 · see citing works
Perry, J. A., Kiezun, A., Tonzi, P., Van Allen, E. M., Carter, S. L., Baca, S. C., Cowley, G. S., Bhatt, A. S., Rheinbay, E., Pedamallu, C. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419260111 · Cited by 481 · see citing works
Tejpar, S., Nollet, F., Li, C., Wunder, J. S., Michils, G., Cin, P. D., Cutsem, E. V., Bapat, B. V., Roy, F. M. V., Cassiman, J. J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1203041 · Cited by 344 · see citing works
Jang, G.-B., Kim, J. Y., Cho, S., Park, K., Jung, J., Lee, H., Hong, I., & Nam, J. (2015) · Scientific Reports · doi:10.1038/srep12465 · Cited by 330 · see citing works
Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta
Grafe, I., Yang, T., Alexander, S., Homan, E. P., Lietman, C., Jiang, M. M., Bertin, T., Munivez, E. M., Chen, Y., Dawson, B., et al. (2014) · Nature Medicine · doi:10.1038/nm.3544 · Cited by 307 · see citing works
Self-citationLentiviral Vectors to Probe and Manipulate the Wnt Signaling Pathway
Fuerer, C., & Nusse, R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009370 · Cited by 287 · see citing works
Hoang, B. H., Kubo, T., Healey, J. H., Yang, R., Nathan, S. S., Kolb, E. A., Mazza, B., Meyers, P. A., & Gorlick, R. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1952 · Cited by 261 · see citing works
Behjati, S., Tarpey, P. S., Haase, K., Ye, H., Young, M. D., Alexandrov, L. B., Farndon, S. J., Collord, G., Wedge, D. C., Martincorena, I., et al. (2017) · Nature Communications · doi:10.1038/ncomms15936 · Cited by 261 · see citing works
Cojoc, M., Peitzsch, C., Kurth, I., Trautmann, F., Kunz‐Schughart, L. A., Телегеев, Г. Д., Stakhovsky, E. A., Walker, J. R., Simin, K. J., Lyle, S. R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1924 · Cited by 222 · see citing works
β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids
Condello, S., Morgan, C. A., Nagdas, S., Cao, L., Turek, J. J., Hurley, T. D., & Matei, D. E. (2014) · Oncogene · doi:10.1038/onc.2014.178 · Cited by 189 · see citing works
Advances in osteosarcoma stem cell research and opportunities for novel therapeutic targets
Yan, G., Lv, Y., & Guo, Q. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.11.003 · Cited by 187 · see citing works
Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasis
Joeng, K. S., Lee, Y., Lim, J., Chen, Y., Jiang, M., Munivez, E. M., Ambrose, C. G., & Lee, B. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92617 · Cited by 181 · see citing works
Self-citationSmall molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells
Bulut, G., Hong, S.-H., Chen, K., Beauchamp, E. M., Rahim, S., Kosturko, G. W., Glasgow, E., Dakshanamurthy, S., Lee, H.-S., Daar, I., et al. (2012) · Oncogene · doi:10.1038/onc.2011.245 · Cited by 179 · see citing works
Hoang, B. H., Kubo, T., Healey, J. H., Sowers, R. S., Mazza, B., Yang, R., Huvos, A. G., Meyers, P. A., & Gorlick, R. G. (2003) · International Journal of Cancer · doi:10.1002/ijc.11677 · Cited by 178 · see citing works
Jang, G.-B., Hong, I., Kim, R., Lee, S., Park, S.-J., Lee, E. S., Park, J. H., Yun, C.-H., Chung, J.-U., Lee, K.-J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2041 · Cited by 164 · see citing works
Awad, O., Yustein, J. T., Shah, P., Gul, N., Katuri, V., O’Neill, A., Kong, Y., Brown, M. L., Toretsky, J. A., & Loeb, D. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013943 · Cited by 159 · see citing works
Self-citationHonoki (2010) · Oncology Reports · doi:10.3892/or_00000885 · Cited by 143 · see citing works
NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma
Zhao, S., Kurenbekova, L., Gao, Y., Roos, A., Creighton, C. J., Rao, P., Hicks, J., Man, T.-K., Lau, C., Brown, A. M. C., et al. (2015) · Oncogene · doi:10.1038/onc.2014.429 · Cited by 139 · see citing works
Self-citationCharacterization of the metastatic phenotype of a panel of established osteosarcoma cells
Ren, L., Mendoza, A., Zhu, J., Briggs, J., Halsey, C., Hong, E. S., Burkett, S. S., Morrow, J. J., Lizardo, M. M., Osborne, T. S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5177 · Cited by 119 · see citing works
Ma, Y., Ren, Y., Han, E. Q., Li, H., Chen, D., Jacobs, J. J., Gitelis, S., O’Keefe, R. J., Konttinen, Y. T., Yin, G., et al. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.12.118 · Cited by 117 · see citing works
Targeting the canonical Wnt/β‐catenin pathway in hematological malignancies
Ashihara, E., Takada, T., & Maekawa, T. (2015) · Cancer Science · doi:10.1111/cas.12655 · Cited by 107 · see citing works
Fiskus, W. C., Sharma, S., Saha, S., Shah, B. N., Devaraj, S. G. T., Sun, B., Horrigan, S. K., Leveque, C. M., Zu, Y., Iyer, S. P., et al. (2014) · Leukemia · doi:10.1038/leu.2014.340 · Cited by 98 · see citing works
Wnt Pathway in Osteosarcoma, from Oncogenic to Therapeutic
Cai, Y., Cai, T., & Chen, Y. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24708 · Cited by 96 · see citing works
Zhao, H., Hou, W., Tao, J., Zhao, Y., Wan, G., Ma, C., & Xu, H. (2016) · Europe PMC (PubMed Central) · Cited by 94 · see citing works
Liu, H., Remedi, M. S., Pappan, K. L., Kwon, G., Rohatgi, N., Marshall, C. A., & McDaniel, M. L. (2008) · Diabetes · doi:10.2337/db07-1208 · Cited by 93 · see citing works
Modeling metastasis biology and therapy in real time in the mouse lung
Mendoza, A., Hong, S.-H., Osborne, T., Khan, M. A., Campbell, K., Briggs, J., Eleswarapu, A., Buquo, L., Ren, L., Hewitt, S. M., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40252 · Cited by 92 · see citing works
Goldstein, S. D., Trucco, M., Guzman, W. B., Hayashi, M., & Loeb, D. M. (2016) · Oncotarget · doi:10.18632/oncotarget.8522 · Cited by 78 · see citing works
Jin, H., Luo, S., Wang, Y., Liu, C., Piao, Z.-H., Xu, M., Guan, W., Li, Q., Zou, H., Tan, Q.-Y., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.06.008 · Cited by 75 · see citing works
Hu, T., Li, C., Cao, Z., Raay, T. J. V., Smith, J. G., Willert, K., Solnica‐Krezel, L., & Coffey, R. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.075945 · Cited by 59 · see citing works
Lin, C. H., Guo, Y., Ghaffar, S., McQueen, P., Pourmorady, J. S., Christ, A. B., Rooney, K., Ji, T., Eskander, R. H., Zi, X., et al. (2013) · Sarcoma · doi:10.1155/2013/147541 · Cited by 57 · see citing works
A systems biology approach reveals common metastatic pathways in osteosarcoma
Flores, R. J., Li, Y., Yu, A. K.-T., Shen, J. J., Rao, P. H., Lau, S. S., Vannucci, M., Lau, C. C., & Man, T. (2012) · BMC Systems Biology · doi:10.1186/1752-0509-6-50 · Cited by 51 · see citing works
Ren, L., Hong, S.-H., Chen, Q.-R., Briggs, J., Cassavaugh, J., Srinivasan, S., Lizardo, M. M., Mendoza, A., Xia, A. Y., Avadhani, N., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-0210 · Cited by 50 · see citing works
Savvidou, I., Khong, T. T., Cuddihy, A. R., McLean, C., Horrigan, S. K., & Spencer, A. G. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0624 · Cited by 50 · see citing works
FHL2 Silencing Reduces Wnt Signaling and Osteosarcoma Tumorigenesis In Vitro and In Vivo
Brun, J., Dieudonné, F., Marty, C., Müller, J. M., Schüle, R., Patiño‐García, A., Lecanda, F., Fromigué, O., & Marie, P. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055034 · Cited by 46 · see citing works
Metabolomics uncovers a link between inositol metabolism and osteosarcoma metastasis
Ren, L., Hong, E. S., Mendoza, A., Issaq, S. H., Hoang, C. T., Lizardo, M. M., LeBlanc, A. K., & Khanna, C. (2017) · Oncotarget · doi:10.18632/oncotarget.15872 · Cited by 46 · see citing works
Zhang, W., Duan, N., Zhang, Q., Song, T., Li, Z., Zhang, C., Chen, X., & Wang, K. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.19032 · Cited by 41 · see citing works
Deng, Z., Niu, G., Cai, L., Wei, R., & Zhao, X. (2013) · BioMed Research International · doi:10.1155/2013/496193 · Cited by 36 · see citing works
Apoptosis Resistance and PKC Signaling: Distinguishing Features of High and Low Metastatic Cells
Hong, S.-H., Ren, L., Mendoza, A., Eleswarapu, A. S., & Khanna, C. (2012) · Neoplasia · doi:10.1593/neo.111498 · Cited by 28 · see citing works
Morrow, J. J., Mendoza, A., Koyen, A., Lizardo, M. M., Ren, L., Waybright, T. J., Hansen, R. J., Gustafson, D. L., Zhou, M., Fan, T. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0326 · Cited by 27 · see citing works
Soldi, R., Horrigan, S. K., Chołody, M., Padia, J. K., Sorna, V., Bearss, J. J., Gilcrease, G. W., Bhalla, K. N., Verma, A. R., Vankayalapati, H., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00460 · Cited by 25 · see citing works
Han, W., & Liu, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.049 · Cited by 21 · see citing works
Flagged first, then by citations
2 of the 49 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660 · see citing works
Spreafico, F., Fernandez, C. V., Brok, J. S., Nakata, K., Vujanic, G. M., Geller, J. I., Gessler, M., Maschietto, M. C., Behjati, S., Polanco, A., et al. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00308-8 · Cited by 219 · see citing works
The Wnt Signalling Pathway: A Tailored Target in Cancer
Koni, M., Pinnarò, V., & Brizzi, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207697 · Cited by 143 · see citing works
Recent and Ongoing Research into Metastatic Osteosarcoma Treatments
Harris, M. A., & Hawkins, C. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073817 · Cited by 143 · see citing works
Fan, T. M., Roberts, R. D., & Lizardo, M. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00013 · Cited by 90 · see citing works
Recent Insights into Therapy Resistance in Osteosarcoma
Prudowsky, Z. D., & Yustein, J. T. (2020) · Cancers · doi:10.3390/cancers13010083 · Cited by 89 · see citing works
Self-citationEvolving strategies for management of desmoid tumor
Riedel, R. F., & Agulnik, M. (2022) · Cancer · doi:10.1002/cncr.34332 · Cited by 84 · see citing works
Canine and murine models of osteosarcoma
Beck, J. A., Ren, L., Huang, S., Berger, E. P., Bardales, K., Mannheimer, J., Mazcko, C. N., & LeBlanc, A. K. (2022) · Veterinary Pathology · doi:10.1177/03009858221083038 · Cited by 79 · see citing works
Research models and mesenchymal/epithelial plasticity of osteosarcoma
Yu, X., Yustein, J. T., & Xu, J. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00600-w · Cited by 77 · see citing works
Self-citationDesmoid tumors: To treat or not to treat, That is the question
Kasper, B., Raut, C. P., & Gronchi, A. (2020) · Cancer · doi:10.1002/cncr.33233 · Cited by 74 · see citing works
The roles of glycolysis in osteosarcoma
Feng, Z., Ou, Y., & Hao, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.950886 · Cited by 60 · see citing works
Zhang, X., Wan, J., Mo, F., Tang, D., Xiao, H., Li, Z., Jia, J., & Liu, T. (2022) · Advanced Science · doi:10.1002/advs.202201819 · Cited by 57 · see citing works
Patient‐derived xenograft models in pan‐cancer: From bench to clinic
Li, J., Gu, A., Tang, N., Zengin, G., Li, M., & Liu, Y. (2025) · Interdisciplinary medicine · doi:10.1002/inmd.20250016 · Cited by 62 · see citing works
Recent Advances in Desmoid Tumor Therapy
Napolitano, A., Mazzocca, A., Ceruso, M. S., Minelli, A., Baldo, F., Badalamenti, G., Silletta, M., Santini, D., Tonini, G., Incorvaia, L., et al. (2020) · Cancers · doi:10.3390/cancers12082135 · Cited by 55 · see citing works
Tirapazamine suppress osteosarcoma cells in part through SLC7A11 mediated ferroptosis
Shi, Y., Gong, M., Deng, Z., Liu, H., Chang, Y., Yang, Z., & Cai, L. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.06.036 · Cited by 55 · see citing works
Singla, A. K., Wang, J., Yang, R., Geller, D. S., Loeb, D. M., & Hoang, B. H. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_8 · Cited by 50 · see citing works
Cancer Stem Cells as a Source of Drug Resistance in Bone Sarcomas
Menéndez, S. T., Gallego, B., Murillo, D., Rodríguez, A., & Rodrı́guez, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122621 · Cited by 48 · see citing works
Wnt/β-catenin–activated Ewing sarcoma cells promote the angiogenic switch
Hawkins, A. G., Pedersen, E. A., Treichel, S., Temprine, K., Sperring, C. P., Read, J. A., Magnuson, B., Chugh, R. K., & Lawlor, E. R. (2020) · JCI Insight · doi:10.1172/jci.insight.135188 · Cited by 47 · see citing works
Targeting ferroptosis in osteosarcoma
Zhao, J., Zhao, Y., Ma, X., Zhang, B., & Feng, H. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100380 · Cited by 46 · see citing works
Schott, C. R., Koehne, A. L., Sayles, L. C., Young, E. P., Luck, C., Yu, K., Lee, A. G., Breese, M. R., Leung, S. G., Xu, H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0873 · Cited by 45 · see citing works
Wang, Y., Li, K., Zhao, W., Liu, Z., Liu, J., Shi, A., Chen, T., Mu, W., Xu, Y., Pan, C., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04451-8 · Cited by 44 · see citing works
Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis
Nirala, B. K., Yamamichi, T., & Yustein, J. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411367 · Cited by 40 · see citing works
Self-citationFeng, Z., Zheng, L., Teng, Y., Tao, S., Wei, X.-A., Zheng, Z., Zheng, B., Zhang, X., Huang, B. H., Liu, J., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04339-7 · Cited by 39 · see citing works
Research progress in the mechanism and treatment of osteosarcoma
Bian, J., Liu, Y., Zhao, X., Meng, C., Zhang, Y., Duan, Y., & Wang, G. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002800 · Cited by 38 · see citing works
Patient-derived xenograft models: Current status, challenges, and innovations in cancer research
Liu, M., & Yang, X. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101520 · Cited by 41 · see citing works
Long noncoding RNA lncARSR confers resistance to Adriamycin and promotes osteosarcoma progression
Shen, P., & Cheng, Y. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2573-2 · Cited by 38 · see citing works
Children's Oncology Group's 2023 blueprint for research: Renal tumors
Geller, J. I., Hong, A. L., Vallance, K., Evageliou, N., Aldrink, J. H., Cost, N. G., Treece, A. L., Renfro, L. A., & Mullen, E. A. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30586 · Cited by 34 · see citing works
Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities
Du, X., Wei, H., Zhang, B., Wang, B., Li, Z., Pang, L. K., Zhao, R., & Yao, W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1117867 · Cited by 31 · see citing works
Schott, C. R., Shah, A. T., & Sweet-Cordero, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_1 · Cited by 30 · see citing works
Advances and challenges in the treatment of osteosarcoma
Wang, X., Zhu, K., Hu, J., & Zhang, C. (2025) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2025.07.001 · Cited by 31 · see citing works
Desmoid Fibromatosis: Management in an Era of Increasing Options
Ratan, R., Roland, C. L., & Bishop, A. J. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01026-w · Cited by 29 · see citing works
What’s in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications
Serafini, M. T., Cargnin, S., Massarotti, A., Tron, G. C., Pirali, T., & Genazzani, A. A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00181 · Cited by 29 · see citing works
Nie, J., Ling, Y., Jin, M., Chen, Z., Liu, W., Shen, W., Fang, T., Li, J., & He, Y. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176009 · Cited by 28 · see citing works
TBL1X: At the crossroads of transcriptional and posttranscriptional regulation
Pray, B. A., Youssef, Y., & Alinari, L. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.09.006 · Cited by 26 · see citing works
Higuchi, T., Sugisawa, N., Miyake, K., Oshiro, H., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Igarashi, K., Bouvet, M., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.06.002 · Cited by 25 · see citing works
Tsang, S. V., Rainusso, N. C., Liu, M., Nomura, M., Patel, T. D., Nakahata, K., Kim, H. R., Huang, S., Rajapakshe, K., Coarfa, C., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02538-w · Cited by 25 · see citing works
Self-citationSerra-Camprubí, Q., Verdaguer, H., Oliveros, W., Lupión-Garcia, N., Llop‐Guevara, A., Molina, C., Vila-Casadesús, M., Turpin, A., Neuzillet, C., Frigola, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2551 · Cited by 25 · see citing works
The potential roles of exosomal noncoding RNAs in osteosarcoma
Li, S., & Wang, X. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30101 · Cited by 22 · see citing works
Targeted therapies in hepatocellular carcinoma: past, present, and future
Gujarathi, R., Franses, J. W., Pillai, A., & Liao, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1432423 · Cited by 21 · see citing works
Choi, S., Lee, J.-H., Kim, R.-K., Jung, U., Kahm, Y.-J., Cho, E., & Kim, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186957 · Cited by 21 · see citing works
Kong, H., Yu, W., Chen, Z., Li, H., Ye, G., Hong, J., Xie, Z., Chen, K., Wu, Y., & Shen, H. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02320-0 · Cited by 22 · see citing works
Yuan, X., Zhang, P., Yu, T., Huang, H., Zhang, L., Yang, C., Tan, T., Yang, S., Luo, X., & Luo, J. (2020) · PubMed Central · Cited by 21 · see citing works
Martins‐Neves, S. R., Sampaio-Ribeiro, G., & Gomes, C. M. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911416 · Cited by 21 · see citing works
Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma
Jubelin, C., Muñoz-García, J., Cochonneau, D., Moranton, E., Heymann, M., & Heymann, D. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.130 · Cited by 19 · see citing works
Penny, M. K., Lerário, A. M., Basham, K. J., Chukkapalli, S., Yu, Y., Mohan, D. R., LaPensee, C. R., Converso‐Baran, K., Hoenerhoff, M. J., Suárez–Fernández, L., et al. (2023) · Cancers · doi:10.3390/cancers15143559 · Cited by 19 · see citing works
Self-citationTBL1X and Flot2 form a positive feedback loop to promote metastasis in nasopharyngeal carcinoma
Xu, H., Yan, X., Zhu, H., Kang, Y., Luo, W., Zhao, J., Zhou, K., Liu, X., Ye, L., Zhou, Q., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.68091 · Cited by 18 · see citing works
Advances in the clinical management of high‐risk Wilms tumors
Ortiz, M. V., Koenig, C., Armstrong, A. E., Brok, J. S., de Camargo, B., Mavinkurve‐Groothuis, A. M. C., Velásquez, T., Venkatramani, R., Woods, A. D., Dome, J. S., et al. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30342 · Cited by 17 · see citing works
Novel therapy for pediatric and adolescent kidney cancer
Walz, A. L., Fernandez, C. V., & Geller, J. I. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09822-4 · Cited by 17 · see citing works
Zhao, J., Zhao, Y., Ma, X., Feng, H., & Jia, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-09080-5 · Cited by 17 · see citing works
Molecular Signaling Pathways as Potential Therapeutic Targets in Osteosarcoma
Dana, P. M., Sadoughi, F., Asemi, Z., & Yousefi, B. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220209110009 · Cited by 16 · see citing works
Savvidou, I., Khong, T. T., Whish, S., Carmichael, I., Sepehrizadeh, T., Mithraprabhu, S., Horrigan, S. K., de Veer, M., & Spencer, A. G. (2022) · Cancers · doi:10.3390/cancers14030840 · Cited by 16 · see citing works
Advances in the clinical management of high‐risk Wilms tumors
Ortiz, M. V., Koenig, C., Armstrong, A. E., Brok, J. S., de Camargo, B., Mavinkurve‐Groothuis, A. M. C., Velásquez, T., Venkatramani, R., Woods, A. D., Dome, J. S., et al. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30153 · Cited by 16 · see citing works
Nayak, A., Streiff, H., Adekoya, O. O., Gonzalez, I., Silva, I., & Shenoy, A. K. (2025) · Cells · doi:10.3390/cells14030178 · Cited by 15 · see citing works
Łowicki, D., & Przybylski, P. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118213 · Cited by 14 · see citing works
Disease and economic burden of surgery in desmoid tumors: a review
Fernandez, M., Bell, T., Tumminello, B., Khan, S., Zhou, S., & Oton, A. B. (2023) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2023.2203915 · Cited by 14 · see citing works
Belling the “cat”: Wnt/β-catenin signaling and its significance in future cancer therapies
Goyal, A., Murkute, S. L., Bhowmik, S., Prasad, C. P., & Mohapatra, P. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189195 · Cited by 14 · see citing works
Wnt/β-catenin signaling pathway in the tumor progression of adrenocortical carcinoma
Tai, Y., & Shang, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1260701 · Cited by 13 · see citing works
Wu, S., Shen, D., & Zhao, L. (2022) · Cancer Management and Research · doi:10.2147/cmar.s343033 · Cited by 13 · see citing works
Chen, L., Wang, M., Lin, Z., Yao, M., Wang, W., Cheng, S., Li, B., Zhang, Y., & Yin, Q. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11173 · Cited by 13 · see citing works
The Significance of the Wnt/β-Catenin Pathway and Related Proteins in Gastrointestinal Malignancies
Romanowicz, A., & Łukaszewicz‐Zając, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178130 · Cited by 12 · see citing works
Zhang, B., Du, X., Fan, Y., Qu, G., Pang, L. K., Zhao, R., & Yao, W. (2023) · iScience · doi:10.1016/j.isci.2023.108272 · Cited by 12 · see citing works
State of the Art Modelling of the Breast Cancer Metastatic Microenvironment: Where Are We?
Nuckhir, M., Withey, D., Cabral, S. C. M., Harrison, H., & Clarke, R. B. (2024) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-024-09567-z · Cited by 12 · see citing works
Giusti, V., Miserocchi, G., Sbanchi, G., Pannella, M., Hattinger, C. M., Cesari, M., Fantoni, L., Guerrieri, A. N., Bellotti, C., Vita, A. D., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12081921 · Cited by 12 · see citing works
Ubiquitination in osteosarcoma: unveiling the impact on cell biology and therapeutic strategies
Shen, J., Lai, Y., Wu, Y., Lin, X. H., Zhang, C., & Liu, H. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0231 · Cited by 13 · see citing works
Huang, X., An, R.-F., & Zhang, W. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220217113719 · Cited by 11 · see citing works
Evaluation of diagnostic algorithm and therapeutic interventions for intra-abdominal desmoid tumors
Mastoraki, A. T., Schizas, D., Vassiliu, S., Saliaris, K., Giagkos, G., Theochari, M., Vergadis, C., Tolia, M., Vassiliu, P., & Felekouras, E. S. (2022) · Surgical Oncology · doi:10.1016/j.suronc.2022.101724 · Cited by 10 · see citing works
Zhao, T., Zhou, T., Zhang, C., Liu, Y., Wang, W., Li, C., Xing, L., & Jiang, H. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00068 · Cited by 11 · see citing works
New treatments for desmoid tumors
Kasper, B. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000953 · Cited by 9 · see citing works
Tegavivint triggers TECR-dependent non-apoptotic cancer cell death
Leak, L. B., Wang, Z., Joseph, A., Johnson, B. A., Chan, A. A., Decosto, C. M., Magtanong, L., Ko, P.-J., Lee, W., Ritho, J., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01913-4 · Cited by 8 · see citing works
Mao, S., Zhang, X., Zhao, Y., Li, X., Wang, Z., Zhou, P., Wang, Z., Zhang, X., Hu, X., Huang, G., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07333-1 · Cited by 9 · see citing works
Selective Targeting of Class I Histone Deacetylases in a Model of Human Osteosarcoma
Torres, H. M., VanCleave, A. M., Vollmer, M. L., Callahan, D., Smithback, A., Conn, J. M., Rodezno, T. G., Gao, Z., Cao, Y. X., Tecleab, Y. A., et al. (2021) · Cancers · doi:10.3390/cancers13164199 · Cited by 9 · see citing works
METTL3/YTHDF1 stabilizes CORO6 expression promoting osteosarcoma progression through glycolysis
Liu, X., Yu, W., Song, W., Zhang, Z., Chen, B., & Lin, H. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.114328 · Cited by 7 · see citing works
Pathobiology and Molecular Pathways Implicated in Osteosarcoma Lung Metastasis: A Scoping Review
Bashir, A., Ismail, A., Mavadia, A., Ghose, A., Ovsepian, S. V., & Boussios, S. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251359716 · Cited by 8 · see citing works
Daley, J. D., Whiteway, S. L., Heske, C. M., Cruz, F. S. D., Whittle, S. B., Cohen‐Gogo, S., Collier, A. B., Gupta, A. K., Ohm, J. E., Clark, A., et al. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31917 · Cited by 7 · see citing works
Impact of scaffold material choice on osteosarcoma phenotype and drug responses in 3D
Monette, C. E., Lee, J., Peasah, A. D., Sayles, L. C., Tai, M., Sweet-Cordero, A., & Yang, F. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.08.046 · Cited by 7 · see citing works
Chen, H., Gong, Z., Zhou, H. W., & Han, Y. K. (2024) · Drug Development Research · doi:10.1002/ddr.22167 · Cited by 7 · see citing works
VanCleave, A. M., Palmer, M., Fang, F., de Oliveira, H. T., Rodezno, T. G., Li, Q., Fuglsby, K., Evans, C. M., Tecleab, Y. A., Ross, A., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27611 · Cited by 7 · see citing works
PTHR1 in osteosarcoma: Specific molecular mechanisms and comprehensive functional perspective
Sun, C., & Li, S. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16420 · Cited by 7 · see citing works
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions
Frankenbach-Désor, T., Niesner, I. C. C., Ahmed, P., Dürr, H. R., Klein, A., Knösel, T., Gospos, J. P., McGovern, J., Hutmacher, D. W., Holzapfel, B. M., et al. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10218-2 · Cited by 7 · see citing works
Jin, K., Shen, C., Yu, W., Lin, J., Zhu, J., Tao, H., & Liu, B. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111420 · Cited by 6 · see citing works
The Role of Pharmacotherapeutic Agents in Children with Desmoid Tumors
Douglass, D. P., Navid, F., & Weiss, A. R. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00526-x · Cited by 5 · see citing works
Targeting WNT5B and WNT10B in osteosarcoma
Miranda‐Carboni, G. A., & Krum, S. A. (2024) · Oncotarget · doi:10.18632/oncotarget.28617 · Cited by 5 · see citing works
Jiang, L., Shen, J., Yang, J., Wang, Z., Tang, L., Li, Y., Liu, J., Li, Z. A., & Liu, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1613657 · Cited by 4 · see citing works
Delijani, K., Hofley, C. M., Luo, N., & Yusin, G. (2020) · Georgetown Medical Review · doi:10.52504/001c.18059 · Cited by 4 · see citing works
Wang, J., Li, H., Wang, H., Li, Q., Bai, X., Lv, H., Nie, C., Chen, B., Xu, W., Tu, S., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.830672 · Cited by 4 · see citing works
Wang, J., Fan, Y., & Xia, L. (2021) · Future Oncology · doi:10.2217/fon-2020-0553 · Cited by 3 · see citing works
Zhang, S., Zhuang, Y., Jin, S., & Wang, K. (2021) · Science of Advanced Materials · doi:10.1166/sam.2021.4140 · Cited by 3 · see citing works
Pan-cancer analysis of role of LOXL4 and experiment validation in osteosarcoma
Chen, W., Xie, F., Lv, J., Huang, D., Zhong, R., Wen, Z., Sun, J., Zheng, S., Liu, W., Zhong, H., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-03761-z · Cited by 3 · see citing works
Li, X., Lin, Z., Liu, Q., Yuan, Y., Luo, H., Zheng, H., & Luo, W. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149130 · Cited by 2 · see citing works
Exploratory Study on CCNB1 and KIF23 as Core Biomarkers of Osteosarcoma
刘, 磊. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1451411 · Cited by 1 · see citing works
Cantoni, C., Vellone, V. G., Cafferata, B., Gaggero, G., Serra, M., Spreafico, F., Bottino, C., & Spaggiari, G. M. (2026) · Cancers · doi:10.3390/cancers18060908 · Cited by 1 · see citing works
Beyond the target: implications of Wnt pathway inhibitors on bone health
Nachef, C., Vanjak, A., Haÿ, E., Cohen-Solal, M. E., & Funck‐Brentano, T. (2026) · Journal of Molecular Medicine · doi:10.1007/s00109-026-02697-3 · Cited by 2 · see citing works
Cohabitation nécessaire et contrariée pour l'enseignement novice
Respaud, S., & Bertone, S. (2004) · EPS: Revue education physique et sport
Genomic and proteomic profiling of osteosarcoma
Patiño‐García, A., & Lecanda, F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821666-8.00054-2
Therapie von Desmoidtumoren: Zeitpunkt und Behandlungsansätze
Kasper, B. (2022) · Die Onkologie · doi:10.1007/s00761-022-01286-6
Huang, P. F., Liu, A., Huang, J., Zhou, R.-Y., Yin, K., Yu, H., & Li, J. (2023) · Research Square · doi:10.21203/rs.3.rs-2885132/v1
Schott, C. R., Koehne, A. L., Sayles, L. C., Young, E. P., Luck, C., Yu, K., Lee, A. G., Breese, M. R., Leung, S. G., Xu, H., et al. (2024) · doi:10.1158/1078-0432.c.7077821.v1
Schott, C. R., Koehne, A. L., Sayles, L. C., Young, E. P., Luck, C., Yu, K., Lee, A. G., Breese, M. R., Leung, S. G., Xu, H., et al. (2024) · doi:10.1158/1078-0432.c.7077821
Preclinical efficacy and safety of Tegavivint in Wnt-activated hepatocellular carcinomaPreprint
Suzuki, T., Curran, C., Drake, T. M., May, S., Swe, K. L. Y., Γεωργακοπούλου, Α., Quince, M., Chalmers, F. E., Paterson, E., Duncan, A. D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.14.738585
- Authors
- Nomura, M., Rainusso, N., Lee, Y.-C., Dawson, B., Coarfa, C., Han, R., Larson, J. L., Shuck, R., Kurenbekova, L., & Yustein, J. T.
- Affiliations
- Baylor College of Medicine (US)
- Corresponding author
- Yustein, Jason T
- ORCID
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-02-21
- Volume
- 111
- Issue
- 11
- Pages
- 1216-1227
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- PMC
- PMC6855956
- OpenAlex
- W2916314601
- Cited by
- 99
- References
- 49
- Citations by year
- 2026: 3 · 2025: 15 · 2024: 13 · 2023: 14 · 2022: 21 · 2021: 15 · 2020: 15 · 2019: 2
- FWCI
- 9.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Prevention and Research Institute of Texas
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- β-catenin, ALDH1, osteosarcoma, Wnt/β-catenin signaling, chemoresistance, lung metastasis, cancer stem cells, patient-derived xenografts, bone integrity, anticancer activity, drug repurposing, mesenchymal stem cells
- MeSH terms
- Aldehyde Dehydrogenase, Animals, Antineoplastic Agents, Bone Neoplasms, Enzyme Inhibitors, Female, Humans, Lung Neoplasms, Male, Osteosarcoma, Tumor Cells, Cultured, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Mice, SCID, Mice, Inbred NOD, Apoptosis, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Proliferation, beta Catenin, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
